Insys sees no change in estimated litigation costs

May 17, 2018

Insys Therapeutics Inc said on Tuesday that it believed a previously estimated $150 million would be sufficient to cover expenses from an ongoing litigation related to the company’s sales practises.


The news comes a day after the U.S. Department of Justice joined a whistleblower lawsuit alleging Insys paid kickbacks to doctors.


The company continues to have an ongoing dialogue with the DOJ regarding this investigation, Insys said on Tuesday.


“This ongoing dialogue has not resulted in information that would cause the company to revise this estimate (of $150 million),” the company said.


The government’s involvement was disclosed in a filing made public on Monday. It adds firepower to the civil litigation as Insys tries to resolve a federal probe into its marketing of Subsys, a spray form of fentanyl.






Share on Facebook
Share on Twitter
Please reload

Featured Posts

Spring Law receiving recognition for outstanding legal services

June 5, 2018

Please reload

Recent Posts
Please reload

Please reload

Search By Tags
Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square
  • Spring Law LinkedIn Page
  • Spring Law Twitter Page

© Copyright Spring Law 2018 | Site created by IMC